| Systematic (IUPAC) name | |
|---|---|
| 5-[(3S,8R,9S,10R,13R,14S,17R)- 14-hydroxy- 10,13-dimethyl- 3-((2R,3R,4R,5R,6R)- 3,4,5-trihydroxy- 6-methyltetrahydro- 2H-pyran-2-yloxy)- 2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro- 1H-cyclopenta[a]phenanthren- 17-yl]- 2H-pyran- 2-one OR 3β-Rhamnosido- 14β-hydroxybufa- 4,20,22-trienolide |
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 466-06-8 |
| ATC code | C01AB01 |
| PubChem | CID 5284613 |
| ChemSpider | 4447658 |
| UNII | KC6BL281EN |
| ChEMBL | CHEMBL600325 |
| Chemical data | |
| Formula | C30H42O8 |
| Mol. mass | 530.650 |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Proscillaridin is a cardiac glycoside, a kind of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). It is of the bufanolide type and can be obtained from plants of the genus Scilla, notably Scilla maritima.[1]
|
||||||||||||||||||||||||||||||||
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)